Company expects enrollment in two YARTEMLEA studies to begin by year-end 2026
Company expects to start OMS527 inpatient clinical trial enrollment by year-end 2026
Omeros targets Phase 1b clinical trial for OMS805 to begin in late 2027
Overview
Biotechnology firm's Q2 net revenue from YARTEMLEA surged 190% quarter-over-quarter
Q2 net income was $13.2 mln; non-GAAP adjusted net income reached $1.8 mln
Company repurchased $30.5 mln in convertible notes and $5.7 mln in shares in Q2
Result Drivers
YARTEMLEA launch - Co attributed Q2 revenue growth to strong demand and market acceptance following the commercial launch of YARTEMLEA, its treatment for TA-TMA
Physician feedback - Co said positive reports from transplant physicians, including in patients unresponsive to prior treatments, supported YARTEMLEA uptake
Novo Nordisk reimbursement - Q2 interest and other income rose due to reimbursement from Novo Nordisk for zaltenibart inventory transfer
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Omeros Corporation is $44.00, about 223.5% above its August 11 closing price of $13.60
OMER•
